A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.

[1]  B. Monk,et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.

[2]  I. Wistuba,et al.  STAT5A-Mediated SOCS2 Expression Regulates Jak2 and STAT3 Activity Following c-Src Inhibition in Head and Neck Squamous Carcinoma , 2011, Clinical Cancer Research.

[3]  D. Armstrong,et al.  Recent progress in the diagnosis and treatment of ovarian cancer , 2011, CA: a cancer journal for clinicians.

[4]  W. Messersmith,et al.  Current status of SRC inhibitors in solid tumor malignancies. , 2011, The oncologist.

[5]  A. Berchuck,et al.  Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells. , 2011, Gynecologic oncology.

[6]  A. Sood,et al.  Functional Roles of Src and Fgr in Ovarian Carcinoma , 2011, Clinical Cancer Research.

[7]  J. Thigpen.  Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer , 2011 .

[8]  C. Spearman.  The proof and measurement of association between two things. , 2015, International journal of epidemiology.

[9]  Christopher Logothetis,et al.  Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. , 2010, Cancer treatment reviews.

[10]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[11]  M. Guarino.  Src signaling in cancer invasion , 2010, Journal of cellular physiology.

[12]  N. Maihle,et al.  Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics , 2010, Journal of ovarian research.

[13]  L. Ploughman,et al.  Biomarker Analyses in Phase 2 Single-Agent Trials of Dasatinib for Breast Cancer. , 2009 .

[14]  Christophe Massard,et al.  Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer , 2009, Clinical Cancer Research.

[15]  G. Scagliotti,et al.  Effects of Src kinase inhibition induced by dasatinib in non–small cell lung cancer cell lines treated with cisplatin , 2009, Molecular Cancer Therapeutics.

[16]  J. Brugge,et al.  Activity of the multikinase inhibitor dasatinib against ovarian cancer cells , 2009, British Journal of Cancer.

[17]  M. Arbushites,et al.  Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  K. Devarajan,et al.  Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. , 2009, Gynecologic oncology.

[19]  F. Lee,et al.  Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor , 2008, Cancer Chemotherapy and Pharmacology.

[20]  Michael W Sill,et al.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Meenakshi Singh,et al.  Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. , 2007, Gynecologic oncology.

[22]  R. Schilder,et al.  Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Steinberg,et al.  A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer , 2007, Cancer.

[24]  Anil Potti,et al.  An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Zheng Yang,et al.  Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure , 2006, Clinical Cancer Research.

[26]  Molly Brewer,et al.  Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Liz Y. Han,et al.  Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. , 2006, Cancer research.

[28]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[29]  D. Agus,et al.  2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth , 2005, Cancer.

[30]  A. Tomassetti,et al.  Simultaneous expression of caveolin-1 and E-cadherin in ovarian carcinoma cells stabilizes adherens junctions through inhibition of src-related kinases. , 2005, The American journal of pathology.

[31]  A. Godwin,et al.  Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study , 2005, Clinical Cancer Research.

[32]  Yolande Pengetnze,et al.  Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3. , 2005, Molecular cancer therapeutics.

[33]  Ping Chen,et al.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.

[34]  Anil K Sood,et al.  Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. , 2004, The American journal of pathology.

[35]  Krystal J Alligood,et al.  A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.

[36]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[37]  R. Edwards,et al.  Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study , 2004, International Journal of Gynecologic Cancer.

[38]  Timothy J. Yeatman,et al.  A renaissance for SRC , 2004, Nature Reviews Cancer.

[39]  Z. Szallasi,et al.  Simultaneous Suppression of Epidermal Growth Factor Receptor and c-erbB-2 Reverses Aneuploidy and Malignant Phenotype of a Human Ovarian Carcinoma Cell Line , 2004, Cancer Research.

[40]  Christopher C. Taylor,et al.  Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line. , 2003, Biochemical and biophysical research communications.

[41]  K. Darcy,et al.  Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Peter F Thall,et al.  Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. , 2003, Gynecologic oncology.

[43]  Richard O Hynes,et al.  Integrins Bidirectional, Allosteric Signaling Machines , 2002, Cell.

[44]  Hong Ma,et al.  Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways , 2002, Oncogene.

[45]  M. Gore,et al.  Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. , 2002, The Lancet. Oncology.

[46]  M. Frame,et al.  Src in cancer: deregulation and consequences for cell behaviour. , 2002, Biochimica et biophysica acta.

[47]  M. Poupon,et al.  Src kinase contributes to the metastatic spread of carcinoma cells , 2002, Oncogene.

[48]  K. Lackey,et al.  The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. , 2001, Cancer research.

[49]  N. Hacker,et al.  Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. , 2001, Journal of the National Cancer Institute.

[50]  J. Nesland,et al.  Caveolin-1 expression in advanced-stage ovarian carcinoma--a clinicopathologic study. , 2001, Gynecologic oncology.

[51]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[52]  N. Hacker,et al.  Anti–sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell–adhesion and tumorigenicity in ovarian cancer cells , 2000, International journal of cancer.

[53]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[54]  R. Bast,et al.  Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  M. Campiglio,et al.  Characteristics of EGFR family‐mediated HRG signals in human ovarian cancer , 1999, Journal of cellular biochemistry.

[56]  J. Mendelsohn,et al.  Augmentation of a humanized Anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225 , 1999, Oncogene.

[57]  T T Chen,et al.  Optimal flexible designs in phase II clinical trials. , 1998, Statistics in medicine.

[58]  R. Bast,et al.  Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. , 1998, Hybridoma.

[59]  P. Sismondi,et al.  The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. , 1996, British Journal of Cancer.

[60]  R. Bast,et al.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.

[61]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[62]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[63]  Nitin R. Patel,et al.  A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables , 1983 .

[64]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[65]  M. Kendall.  The treatment of ties in ranking problems. , 1945, Biometrika.

[66]  M. Kendall.  Statistical Methods for Research Workers , 1937, Nature.

[67]  R. Fisher,et al.  Statistical Methods for Research Workers , 1930, Nature.

[68]  D.,et al.  Regression Models and Life-Tables , 2022 .